“Bottom line - we really don't have any hard dat
Post# of 144713
Great post. NP doesn’t seem akin to unblinding the data, or at least he didn’t during the CC. Correct me if I’m wrong, but I believe someone asked the question about unblinding and he referred to the DSMC’s decision. Maybe with remdesevir’s approval, and pending EUAs/approvals for Regeneron and Eli Lilly, maybe he’ll consider it.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)